Shares of Dr. Reddy's Laboratories Ltd (NYSE:RDY - Get Free Report) have been given an average recommendation of "Moderate Buy" by the five research firms that are presently covering the company, Marketbeat Ratings reports. Two research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has issued a strong buy rating on the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $16.95.
A number of research firms have issued reports on RDY. Hsbc Global Res upgraded Dr. Reddy's Laboratories from a "hold" rating to a "strong-buy" rating in a report on Thursday, June 5th. HSBC upgraded Dr. Reddy's Laboratories from a "hold" rating to a "buy" rating and increased their price target for the stock from $14.44 to $16.90 in a report on Thursday, June 5th. Finally, Zacks Research upgraded Dr. Reddy's Laboratories from a "strong sell" rating to a "hold" rating in a report on Friday, August 15th.
Check Out Our Latest Report on RDY
Dr. Reddy's Laboratories Trading Down 0.2%
Shares of Dr. Reddy's Laboratories stock traded down $0.03 on Friday, reaching $14.64. 903,367 shares of the company's stock were exchanged, compared to its average volume of 772,836. The company has a market capitalization of $12.22 billion, a P/E ratio of 22.17, a price-to-earnings-growth ratio of 5.92 and a beta of 0.32. Dr. Reddy's Laboratories has a 52 week low of $12.26 and a 52 week high of $16.19. The firm's 50-day moving average is $14.32 and its two-hundred day moving average is $14.13. The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.36 and a current ratio of 1.89.
Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) last posted its quarterly earnings results on Wednesday, July 23rd. The company reported $0.20 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.18 by $0.02. The firm had revenue of $988.82 million for the quarter, compared to analysts' expectations of $88.27 billion. Dr. Reddy's Laboratories had a return on equity of 17.25% and a net margin of 16.99%. Sell-side analysts predict that Dr. Reddy's Laboratories will post 0.8 EPS for the current fiscal year.
Dr. Reddy's Laboratories Increases Dividend
The company also recently announced an annual dividend, which was paid on Wednesday, August 6th. Investors of record on Thursday, July 10th were issued a $0.0915 dividend. The ex-dividend date was Friday, July 25th. This represents a dividend yield of 62.4%. This is an increase from Dr. Reddy's Laboratories's previous annual dividend of $0.08. Dr. Reddy's Laboratories's dividend payout ratio (DPR) is 10.61%.
Hedge Funds Weigh In On Dr. Reddy's Laboratories
A number of large investors have recently modified their holdings of RDY. Deutsche Bank AG raised its position in Dr. Reddy's Laboratories by 311.9% in the 4th quarter. Deutsche Bank AG now owns 171,602 shares of the company's stock valued at $2,710,000 after buying an additional 129,936 shares during the last quarter. National Bank of Canada FI raised its position in Dr. Reddy's Laboratories by 331.2% in the 1st quarter. National Bank of Canada FI now owns 71,000 shares of the company's stock valued at $936,000 after buying an additional 54,536 shares during the last quarter. Bessemer Group Inc. raised its position in Dr. Reddy's Laboratories by 10.3% in the 1st quarter. Bessemer Group Inc. now owns 863,880 shares of the company's stock valued at $11,395,000 after buying an additional 81,024 shares during the last quarter. Jump Financial LLC raised its position in Dr. Reddy's Laboratories by 534.1% in the 1st quarter. Jump Financial LLC now owns 147,111 shares of the company's stock valued at $1,940,000 after buying an additional 123,911 shares during the last quarter. Finally, GAMMA Investing LLC raised its position in Dr. Reddy's Laboratories by 971.5% in the 1st quarter. GAMMA Investing LLC now owns 72,848 shares of the company's stock valued at $961,000 after buying an additional 66,049 shares during the last quarter. 3.85% of the stock is currently owned by institutional investors.
About Dr. Reddy's Laboratories
(
Get Free Report)
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.
Further Reading
Before you consider Dr. Reddy's Laboratories, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dr. Reddy's Laboratories wasn't on the list.
While Dr. Reddy's Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
